{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:35:39Z","timestamp":1782758139133,"version":"3.54.5"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Suzhou Science and Technology Plan Project","award":["SKYD2023173"],"award-info":[{"award-number":["SKYD2023173"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,17]]},"abstract":"<jats:p>Drug-induced neutropenia (DIN) deserves both clinicians\u2019 and researchers\u2019 attention for the serious clinical consequences. This study aimed to conduct an exploratory analysis of DIN reports in the United States Food and Drug Administration Adverse Event Reporting System database to identify drugs associated with neutropenia. A disproportionality analysis of DIN was conducted using reports submitted to the United States Food and Drug Administration Adverse Event Reporting System from the first quarter of 2004 to the fourth quarter of 2024. Both the reporting odds ratio algorithms and the information component were applied to identify an association between target drugs and DIN events. A total of 223,736 DIN cases were found, and 254 drugs were identified as potentially associated with neutropenia. The top-ranked drug categories were \u201cmonoclonal antibodies and antibody-drug conjugates,\u201d \u201cother antineoplastic agents,\u201d \u201cprotein kinase inhibitors,\u201d \u201cdirect-acting antivirals,\u201d \u201cantimetabolites,\u201d \u201calkylating agents,\u201d and \u201cimmunosuppressants.\u201d The top 5 drugs ranked by number of cases were clozapine, lenalidomide, rituximab, palbociclib, and carboplatin. The top 5 drugs ranked by reporting odds ratio signal strength were calcium levofolinate, vinorelbine, gemtuzumab ozogamicin, fludarabine, and daunorubicin. This comprehensive pharmacovigilance study identified drugs potentially associated with neutropenia, which can help clinicians and researchers further understand DIN.<\/jats:p>","DOI":"10.1097\/md.0000000000048434","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:01:58Z","timestamp":1776434518000},"page":"e48434","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Drug-induced neutropenia: A comprehensive pharmacovigilance study of the FAERS database"],"prefix":"10.1097","volume":"105","author":[{"given":"Jie","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Zhangjiagang TCM Hospital, Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Taicang TCM Hospital, Affiliated to Nanjing University of Chinese Medicine, Taicang, Jiangsu, China, Taicang, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhangjiagang TCM Hospital, Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Jia","sequence":"additional","affiliation":[{"name":"Nursing Department, Taicang TCM Hospital, Affiliated to Nanjing University of Chinese Medicine, Taicang, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6719-3461","authenticated-orcid":false,"given":"Jinfeng","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9245-7275","authenticated-orcid":false,"given":"Zhitao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhangjiagang TCM Hospital, Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260605","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2991\/chi.k.210216.001","article-title":"How to make the right diagnosis in neutropenia.","volume":"3","author":"Solomou","year":"2021","journal-title":"Clin Hematol Int"},{"key":"R2-20260605","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/MOH.0000000000000305","article-title":"An update on the diagnosis and treatment of chronic idiopathic neutropenia.","volume":"24","author":"Dale","year":"2017","journal-title":"Curr Opin Hematol"},{"key":"R3-20260605","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"key":"R4-20260605","doi-asserted-by":"crossref","first-page":"95","DOI":"10.21307\/immunohematology-2019-103","article-title":"Drug-induced immune neutropenia\/agranulocytosis.","volume":"30","author":"Curtis","year":"2014","journal-title":"Immunohematology"},{"key":"R5-20260605","first-page":"299","article-title":"Idiosyncratic drug-induced neutropenia & agranulocytosis.","volume":"110","author":"Andr\u00e8s","year":"2017","journal-title":"QJM"},{"key":"R6-20260605","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bcpt.12418","article-title":"Non-chemotherapy-induced agranulocytosis detected by a prospective pharmacovigilance program in a tertiary hospital.","volume":"117","author":"Medrano-Casique","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R7-20260605","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/0897190014546115","article-title":"Nonchemotherapy drug-induced neutropenia and agranulocytosis: could medications be the culprit?","volume":"27","author":"Pick","year":"2014","journal-title":"J Pharm Pract"},{"key":"R8-20260605","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/asheducation-2017.1.187","article-title":"Non-chemotherapy drug-induced neutropenia: key points to manage the challenges.","volume":"2017","author":"Curtis","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R9-20260605","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","article-title":"Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed?","volume":"27","author":"Boccia","year":"2022","journal-title":"Oncologist"},{"key":"R10-20260605","doi-asserted-by":"crossref","first-page":"e872","DOI":"10.1097\/HS9.0000000000000872","article-title":"The European guidelines on diagnosis and management of neutropenia in adults and children: a consensus between the European Hematology Association and the EuNet-INNOCHRON COST Action.","volume":"7","author":"Fioredda","year":"2023","journal-title":"Hemasphere"},{"key":"R11-20260605","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/14740338.2023.2278700","article-title":"Drug-induced hypoglycemia: a disproportionality analysis of the FAERS database.","volume":"23","author":"Li","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"R12-20260605","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.anl.2022.12.012","article-title":"Drug-induced olfactory and gustatory dysfunction: analysis of FDA adverse events reporting system.","volume":"50","author":"Debbaneh","year":"2023","journal-title":"Auris Nasus Larynx"},{"key":"R13-20260605","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/jcph.2389","article-title":"An updated comprehensive pharmacovigilance study of drug-induced thrombocytopenia based on FDA Adverse Event Reporting System data.","volume":"64","author":"Kunyu","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"R14-20260605","doi-asserted-by":"crossref","first-page":"1641747","DOI":"10.3389\/fphar.2025.1641747","article-title":"Drug-induced agranulocytosis: a disproportionality analysis and umbrella review.","volume":"16","author":"Lu","year":"2025","journal-title":"Front Pharmacol"},{"key":"R15-20260605","doi-asserted-by":"crossref","first-page":"104015","DOI":"10.1016\/j.msard.2022.104015","article-title":"Ocrelizumab-related neutropenia: effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS).","volume":"65","author":"Hammer","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"R16-20260605","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jamia\/ocv063","article-title":"Use of data mining at the Food and Drug Administration.","volume":"23","author":"Duggirala","year":"2016","journal-title":"J Am Med Inform Assoc"},{"key":"R17-20260605","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/pds.2014","article-title":"Selected control events and reporting odds ratio in signal detection methodology.","volume":"19","author":"Ooba","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R18-20260605","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1109\/TITB.2005.855566A","article-title":"Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance.","volume":"9","author":"Roux","year":"2005","journal-title":"IEEE Trans Inf Technol Biomed"},{"key":"R19-20260605","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.1996.tb01641.x","article-title":"Drugs in the aetiology of agranulocytosis and aplastic anaemia.","volume":"60","author":"Kaufman","year":"1996","journal-title":"Eur J Haematol Suppl"},{"key":"R20-20260605","first-page":"373","article-title":"Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US.","volume":"32","author":"Flanigan","year":"2024","journal-title":"Support Care Cancer"},{"key":"R21-20260605","first-page":"3131","article-title":"The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.","volume":"23","author":"Wang","year":"2015","journal-title":"Support Care Cancer"},{"key":"R22-20260605","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/03007995.2018.1558851","article-title":"Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment.","volume":"35","author":"Weycker","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"R23-20260605","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40265-020-01311-1","article-title":"Isatuximab: first approval.","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"R24-20260605","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab govitecan: first approval.","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"R25-20260605","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-021-01561-7","article-title":"Amivantamab: first approval.","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"R26-20260605","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-022-01677-4","article-title":"Maribavir: first approval.","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"R27-20260605","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0735-6757(98)90138-3","article-title":"Prolonged oral acyclovir administration associated with neutropenia and thrombocytopenia.","volume":"16","author":"Grella","year":"1998","journal-title":"Am J Emerg Med"},{"key":"R28-20260605","first-page":"181","article-title":"Neutropenia related to valacyclovir and valganciclovir in 2 renal transplant patients and treatment with granulocyte colony stimulating factor: a case report.","volume":"8","author":"Keles","year":"2010","journal-title":"Exp Clin Transplant"},{"key":"R29-20260605","doi-asserted-by":"crossref","first-page":"e13185","DOI":"10.1111\/tid.13185","article-title":"Neutropenia and renal dysfunction due to intravesical cidofovir for virus-associated hemorrhagic cystitis after kidney and allogenic hematopoietic stem cell transplantations.","volume":"21","author":"Shimizu","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"R31-20260605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11904-018-0370-7","article-title":"The dual role of neutrophils in HIV infection.","volume":"15","author":"Hensley-McBain","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"key":"R32-20260605","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/08830185.2014.893301","article-title":"Neutropenia during HIV infection: adverse consequences and remedies.","volume":"33","author":"Shi","year":"2014","journal-title":"Int Rev Immunol"},{"key":"R33-20260605","doi-asserted-by":"crossref","first-page":"e0170753","DOI":"10.1371\/journal.pone.0170753","article-title":"Incidence of severe neutropenia in HIV-infected people starting antiretroviral therapy in West Africa.","volume":"12","author":"Leroi","year":"2017","journal-title":"PLoS One"},{"key":"R34-20260605","doi-asserted-by":"crossref","first-page":"634386","DOI":"10.3389\/fimmu.2021.634386","article-title":"Interactions of HIV and antiretroviral therapy with neutrophils and platelets.","volume":"12","author":"Madzime","year":"2021","journal-title":"Front Immunol"},{"key":"R35-20260605","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1177\/135965350501000510","article-title":"Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in C\u00f4te d\u2019Ivoire.","volume":"10","author":"Moh","year":"2005","journal-title":"Antivir Ther"},{"key":"R36-20260605","first-page":"405","article-title":"Neutropenia in human immunodeficiency virus infection: data from the Women\u2019s Interagency HIV Study.","volume":"166","author":"Levine","year":"2006","journal-title":"Arch Intern Med"},{"key":"R37-20260605","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12874-021-01258-1","article-title":"Guidelines are needed for studies of pre-treatment HIV drug resistance: a methodological study.","volume":"21","author":"Mbuagbaw","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"R38-20260605","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/v14061325","article-title":"Direct-acting antiviral agents for hepatitis C virus infection-from drug discovery to successful implementation in clinical practice.","volume":"14","author":"Dietz","year":"2022","journal-title":"Viruses"},{"key":"R39-20260605","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"R40-20260605","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1186\/s12879-021-06506-9","article-title":"Autoimmune neutropenia associated with influenza virus infection in childhood: a case report.","volume":"21","author":"Caballero","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R41-20260605","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial.","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R42-20260605","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/jhep.2002.36502","article-title":"Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.","volume":"36","author":"Soza","year":"2002","journal-title":"Hepatology"},{"key":"R43-20260605","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3949\/ccjm.71.Suppl_3.S17","article-title":"Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.","volume":"71","author":"Ong","year":"2004","journal-title":"Cleve Clin J Med"},{"key":"R44-20260605","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12883-018-1183-4","article-title":"A case of alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.","volume":"18","author":"Vakrakou","year":"2018","journal-title":"BMC Neurol"},{"key":"R45-20260605","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in multiple sclerosis: mechanism of action and beyond.","volume":"16","author":"Ruck","year":"2015","journal-title":"Int J Mol Sci"},{"key":"R46-20260605","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0140-6736(97)09278-7","article-title":"Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.","volume":"350","author":"Nashan","year":"1997","journal-title":"Lancet"},{"key":"R47-20260605","doi-asserted-by":"crossref","first-page":"9429265","DOI":"10.1155\/2018\/9429265","article-title":"Drug-induced hematological cytopenia in kidney transplantation and the challenges it poses for kidney transplant physicians.","volume":"2018","author":"Khalil","year":"2018","journal-title":"J Transplant"},{"key":"R49-20260605","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3390\/cancers16051023","article-title":"Management of adverse events associated with pomalidomide-based combinations in patients with relapsed\/refractory multiple myeloma.","volume":"16","author":"Nadeem","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R50-20260605","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3892\/mco.2023.2705","article-title":"Lenalidomide use in multiple myeloma (Review).","volume":"20","author":"Zhang","year":"2023","journal-title":"Mol Clin Oncol"},{"key":"R51-20260605","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0009-8981(00)00297-7","article-title":"In vitro effects of mycophenolic acid on cell cycle and activation of human lymphocytes.","volume":"300","author":"Heinschink","year":"2000","journal-title":"Clin Chim Acta"},{"key":"R52-20260605","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R53-20260605","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/jgh3.12955","article-title":"Long-term safety and effectiveness of azathioprine in the management of inflammatory bowel disease: a real-world experience.","volume":"7","author":"Yewale","year":"2023","journal-title":"JGH Open"},{"key":"R54-20260605","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.12659\/AJCR.917282","article-title":"Calcineurin inhibitors and neutropenia: is cyclosporine superior to tacrolimus?","volume":"20","author":"Duggal","year":"2019","journal-title":"Am J Case Rep"},{"key":"R55-20260605","doi-asserted-by":"crossref","first-page":"690","DOI":"10.2215\/CJN.07320810","article-title":"Tacrolimus-induced neutropenia in renal transplant recipients.","volume":"6","author":"De Rycke","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R56-20260605","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/petr.12188","article-title":"Tacrolimus-induced neutropenia in a cardiac transplant patient.","volume":"18","author":"Amorim","year":"2014","journal-title":"Pediatr Transplant"},{"key":"R57-20260605","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1532\/IJH97.E0213","article-title":"Bone marrow hypoplasia complicating tacrolimus (FK506) therapy.","volume":"79","author":"Nosari","year":"2004","journal-title":"Int J Hematol"},{"key":"R58-20260605","first-page":"6640681","article-title":"Late-onset neutropenia in long-term clozapine use and its management utilizing prophylactic G-CSF.","volume":"2021","author":"O\u2019 Neill","year":"2021","journal-title":"Case Rep Psychiatry"},{"key":"R59-20260605","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.schres.2024.08.018","article-title":"The timing and severity of clozapine-associated neutropenia in the US: is the risk overstated?","volume":"272","author":"Brandt","year":"2024","journal-title":"Schizophr Res"},{"key":"R60-20260605","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S2215-0366(24)00097-X","article-title":"Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland.","volume":"11","author":"Rubio","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"R61-20260605","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/JCP.0000000000000310","article-title":"Positive symptoms are associated with clinicians\u2019 global impression in treatment-resistant schizophrenia.","volume":"35","author":"Lee","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"R62-20260605","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/JCP.0000000000000467","article-title":"Successful use of single doses of granulocyte-colony stimulating factor (G-CSF) in the treatment of late-onset agranulocytosis associated with clozapine in a patient with treatment-resistant schizophrenia: a case report.","volume":"36","author":"Comacchio","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"R63-20260605","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/11534470-000000000-00000","article-title":"Modified-irinotecan\/fluorouracil\/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.","volume":"30","author":"Yuuki","year":"2010","journal-title":"Clin Drug Investig"},{"key":"R64-20260605","doi-asserted-by":"crossref","first-page":"1758835919853954","DOI":"10.1177\/1758835919853954","article-title":"Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data.","volume":"11","author":"Ratti","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"R65-20260605","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00228-025-03849-z","article-title":"Signal detection of ferric carboxymaltose-induced serious adverse events: disproportionality analysis of FAERS and VigiBase data and systematic review of case reports.","volume":"81","author":"Galigutta","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"key":"R66-20260605","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/14740338.2024.2392860","article-title":"Ocular adverse events associated with platins: a disproportionality analysis of pharmacovigilance data and extensive systematic review of case reports.","volume":"24","author":"Hasik","year":"2025","journal-title":"Expert Opin Drug Saf"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:01:32Z","timestamp":1780675292000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":64,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048434","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"2025-10-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}